Hemophilia B
📧 Sign up to get email alerts when something new happens for Hemophilia B.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH
Authorised gene therapy Hemgenix (etranacogene dezaparvovec) for Hemophilia B with conditional approval by EMA.
-
EMA approval · 2026-07-16EMA Authorised: Hympavzi (marstacimab) — Pfizer Europe MA EEIG
EMA authorised Hympavzi (marstacimab) for hemophilia A and B, expanding treatment options for these conditions.
-
EMA approval · 2026-07-14EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH
The EMA has authorised Hemgenix (etranacogene dezaparvovec) for Hemophilia B under conditional approval as an orphan medicine.
-
EMA approval · 2026-07-06EMA Authorised: Alprolix (eftrenonacog alfa) — Swedish Orphan Biovitrum AB (publ)
Authorised status for Alprolix (eftrenonacog alfa) by Swedish Orphan Biovitrum AB, approved for Hemophilia B.